PolyPid shifts D-PLEX100 into regulatory submission planning, starts commercial prep
PolyPid Ltd. said Q1 2026 marked a shift from late-stage clinical trials to regulatory submission planning for D-PLEX100, its lead candidate to prevent surgical site infections in abdominal colorectal surgery. Management also kicked off commercial preparation activities, outlining plans for manufacturing scale-up and U.S. market entry.
1. Transition to Regulatory Submission Planning
During Q1 2026, PolyPid advanced D-PLEX100 out of late-stage clinical development and into regulatory submission planning. The company began compiling trial data, quality documentation and regulatory filings to support a future approval application for preventing surgical site infections in abdominal colorectal procedures.
2. Commercial Preparation Efforts
PolyPid initiated commercial readiness activities aimed at supporting a U.S. launch of D-PLEX100. These efforts include assessing manufacturing scale-up requirements, establishing distribution logistics and developing initial marketing strategies targeted at hospital networks specializing in colorectal surgery.